Researchers from the National Institutes of Health (NIH) recently outlined plans in Neuron of a project that aims to accelerate research on Alzheimerâs disease and related dementias (ADRD). The ambitious project â the Induced Pluripotent Stem Cell Neurodegenerative Disease Initiative (iNDI) â will model more than 100 mutations associated with ADRD in isogenic induced pluripotent stem cell (iPSC) lines. To learn about some of the main challenges associated with generating a large library of edited iPSCs and the role that Synthego, a genome engineering company, is playing in the iNDI project, we spoke to Synthegoâs CSO, Dr Robert Dean. Anna MacDonald (AM): Why is reliance on a âone gene at a timeâ approach to Alzheimerâs disease research and therapeutic discovery insufficient?